Iktos entered a multi-target AI drug discovery partnership with Servier valued at over EUR1 billion.
Iktos leverages cutting-edge AI and robotics to transform drug discovery, integrating generative AI with automated synthesis and testing to accelerate the development of new treatments
Iktos leverages cutting-edge AI and robotics to transform drug discovery, integrating generative AI with automated synthesis and testing to accelerate the development of new treatments.